[Pharmaceuticals and Medical Devices Agency (PMDA)'s new action for Pharmaceutical Affairs Consultation on Research and Development (R&D) Strategy].
Universities, research institutions, and venture capitals that possess promising "seed" research or technologies in Japan, are not always familiar with development strategies that lead to commercialization of the products in spite of their excellent science and research. In order to create innovative pharmaceuticals and medical devices originating from Japan, Pharmaceuticals and Medical Devices Agency (PMDA) launched new scientific consultation service, named 'Pharmaceutical Affairs Consultation on R&D Strategy' for universities, research institutions, and venture capitals on July 1, 2011. Through these consultations, the guidance and advice on the tests needed in the early development stage and the necessary clinical trials would be provided toward commercialization.
Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. masuyama-koichi@mhlw.go.jp
Koichi
K
Masuyama
D002986:Clinical Trials as Topic / Q000592:standards; D018795:Device Approval / Q000592:standards*; D017277:Drug Approval / Q000458:organization & administration*; D055808:Drug Discovery / Q000592:standards*; D004867:Equipment Design / Q000592:standards*; D004869:Equipment Safety; D006077:Government Agencies; D006801:Humans; D007564:Japan